SCHEMBL6949517

SCHEMBL6949517

Cc1nc(OCCCc2ccncc2)c([N+](=O)[O-])c(N2CCc3ccccc3CC2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGMT P16455 2/20 0.41
HRH4 Q9H3N8 3/20 0.38
CYP19A1 P11511 2/20 0.37
CYP11B1 P15538 2/20 0.37
CYP11B2 P19099 2/20 0.37
MAPT P10636 2/20 0.37
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
HTT P42858 1/20 0.35
POLB P06746 2/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
EED O75530 1/20 0.33
GPR119 Q8TDV5 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6955505 0.93 MGMT (0.47) MGMTHRH4MAPTSMN1; SMN2HTT
SCHEMBL6955543 0.90 MGMT (0.41) MGMTHRH4CYP19A1CYP11B1CYP11B2
SCHEMBL6949119 0.87 MGMT (0.39) MGMTHRH4MAPTSMN1; SMN2HTT
SCHEMBL6953559 0.86 MAPT (0.49) MGMTMAPTSMN1; SMN2HTTPOLB
SCHEMBL6949472 0.85 MGMT (0.42) MGMTHRH4MAPTSMN1; SMN2HTT
SCHEMBL6948575 0.85 MGMT (0.42) MGMTMAPTSMN1; SMN2HTTPOLB
SCHEMBL6951003 0.84 MGMT (0.42) MGMTMAPTSMN1; SMN2HTTPOLB
SCHEMBL6945292 0.84 MGMT (0.45) MGMTMAPTSMN1; SMN2HTTPOLB
SCHEMBL6957503 0.83 MGMT (0.44) MGMTHRH4MAPTSMN1; SMN2HTT
SCHEMBL6945500 0.83 ALDH1A1 (0.48) CYP19A1POLBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed